A — Agilent Technologies, Inc. stock price, charts and financials

QT67Agilent Technologies, Inc.

Agilent Technologies, Inc. (NYSE: A) is a Healthcare company in the Medical - Diagnostics & Research industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.

Latest market price
148.10
+2.13+1.46%
AQT67Agilent Technologies, Inc.·NYSE
148.10+1.46%
TA
Loading chart...
Screen all →
Snapshot
IndexS&P 500P/E29.25EPS (ttm)4.99Insider Own0.57%Shs Outstand282.43MPerf Week5.49%
Market Cap41.23BForward P/E22.11EPS next Y6.60Insider Trans-0.10%Shs Float281.47MPerf Month9.27%
Enterprise Value42.77BPEG1.29EPS next Q1.49Inst Own61.67%Short Float2.68%Perf Quarter23.03%
Income1.41BP/S5.70EPS this Y21.64%Inst Trans-Short Ratio3.20Perf Half Y12.60%
Sales7.23BP/B5.80EPS next Y8.98%ROA10.82%Short Interest7.54MPerf YTD7.28%
Book/sh-P/C28.45EPS next 5Y9.83%ROE20.84%52W High162.61 -8.92%Perf Year28.91%
Cash/sh-P/FCF32.82EPS past 3/5Y3.02% 14.72%ROIC12.54%52W Low109.94 34.72%Perf 3Y14.30%
Dividend Est.1.02 (0.69%)EV/EBITDA21.80Sales past 3/5Y0.48% 5.41%Gross Margin53.00%Volatility2.61% 2.67%Perf 5Y-4.74%
Dividend TTM1.01 (0.68%)EV/Sales5.91EPS Y/Y TTM12.42%Oper. Margin21.50%ATR (14)3.93Perf 10Y207.24%
Dividend Ex-DateJun 30, 2026Quick Ratio1.62Sales Y/Y TTM11.09%Profit Margin19.55%RSI (14)69.83Recom2.22
Dividend Gr. 3/5Y-11.27% 6.62%Current Ratio2.10EPS Q/Q13.74%SMA206.17%Beta1.22Target Price153.25
Payout20.16%Debt/Eq0.47Sales Q/Q10.01%SMA508.66%Rel Volume0.65Prev Close145.97
Employees18,100LT Debt/Eq0.45EarningsAug 26SMA20011.41%Avg Volume2.34MPrice148.10
IPO DateNov 18, 1999Option/ShortYes / YesEPS/Sales Surpr.5.79% 2.03%Net Debt/EBITDA0.79Volume1,525,050Change1.46%
Analyst Ratings
DateActionAnalystRatingTarget
Jul-06-26ReiteratedEvercore ISI GroupOutperform$160$148
Jun-11-26DowngradePiper SandlerOverweightNeutral$150
Jun-03-26ReiteratedHSBCBuy$180$165
May-28-26ReiteratedRobert W. Baird$156$158
May-28-26ReiteratedWells FargoOverweight$165$160
May-28-26ReiteratedRBC CapitalOutperform$153$155
May-28-26UpgradeB of A SecuritiesNeutralBuy
May-26-26InitiatedRBC CapitalOutperform$153
May-26-26ReiteratedRobert W. Baird$155$156
Apr-14-26ReiteratedBarclaysOverweight$165$140
Latest News
Aug-05-26
Jul-30-26
Jul-29-26
Jul-28-26
Jul-23-26
Jul-21-26
Jul-20-26
Jul-17-26
Jul-15-26
Jul-14-26
Jul-09-26
Jul-08-26
Jul-07-26
Company

Agilent Technologies, Inc. delivers specialized, application-focused technologies and services to the global life sciences, diagnostics, and applied chemistry industries. Its Life Sciences and Applied Markets segment provides a comprehensive portfolio of analytical instrumentation. This includes liquid chromatography (LC) and gas chromatography (GC) systems, often integrated with mass spectrometry (MS) for advanced analysis (LC-MS, GC-MS). They also offer inductively coupled plasma mass spectrometry (ICP-MS), atomic absorption (AA), microwave plasma-atomic emission spectrometry (MP-AES), and inductively coupled plasma optical emission spectrometry (ICP-OES) instruments, alongside Raman spectroscopy for material characterization. Beyond spectroscopy, the segment supplies cell analysis solutions such as plate-based assays, flow cytometers, real-time cell analyzers, imaging systems, and microplate readers. Complementing these are various laboratory software, information management platforms, data analytics tools, automated and robotic lab systems, dissolution testing equipment, vacuum technology, and general measurement solutions. The Diagnostics and Genomics division offers cutting-edge tools for genetic and diagnostic research. These encompass arrays designed for DNA mutation detection, genotyping, gene copy number determination, identification of gene rearrangements, DNA methylation profiling, and gene expression analysis. This segment also provides target enrichment solutions for next-generation sequencing, along with software for genetic data management and interpretation. Furthermore, it synthesizes custom oligonucleotides. Other significant offerings include immunohistochemistry (IHC), in situ hybridization (ISH), hematoxylin and eosin (H&E) staining, and specialized staining solutions. The division also supplies consumables and software essential for quality control analysis of nucleic acid samples, as well as reagents for turbidimetry and flow cytometry applications. A key area of development for this segment is liquid-based pharmacodiagnostics. Agilent CrossLab, the third segment, focuses on providing essential laboratory consumables and services. Its product range features GC and LC columns, products for sample preparation, custom chemical formulations, and various supplies for laboratory instruments. Complementary services include expert support for startup, ongoing operations, training, compliance, Software-as-a-Service (SaaS) offerings, asset management, and professional consultation. The company's products reach customers through a diverse sales network, including direct sales teams, distributors, resellers, manufacturer's representatives, and its e-commerce platforms. Agilent Technologies, Inc. was established in 1999 and maintains its corporate headquarters in Santa Clara, California.

Ownership
Total institutional ownership61.67%

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
TTM
FY 2025
10/31/2025
FY 2024
10/31/2024
FY 2023
10/31/2023
FY 2022
10/31/2022
FY 2021
10/31/2021
FY 2020
10/31/2020
FY 2019
10/31/2019
FY 2018
10/31/2018
Total Revenue7,2326,9486,510
Cost of Goods Sold Incl. D&A3,3993,3052,975
Gross Profit3,8333,6433,535
Selling, General and Administrative Excl. Other1,7861,7091,518
Research and Development473455479
Other Operating Expense19050
Operating Income1,5551,4791,488
Interest Expense10511296
Unusual Expense
Non-Operating Income (Expense)13068129
Net Income Before Taxes1,5801,4351,521
Income Taxes166132232
Consolidated Net Income1,4141,3031,289
Net Income From Continuing Operations1,4141,3031,289
Net Income1,4141,3031,289
EPS (Recurring)4.994.594.44
EPS (Basic, Before Extraordinaries)4.994.594.44
EPS (Diluted)4.984.574.43
EBITDA1,9621,8351,874
Other After Tax Adjustments
Stock Option Compensation Expense
Price To Earnings Ratio29.7432.0329.42
Price To Sales Ratio5.805.965.80
Gross Margin53.0052.4354.30
Operating Margin21.5021.2922.86
Net Margin19.5518.7519.80
Shares Outstanding283283290
Market Capitalization41,91441,42037,790
Operating Lease Expense
Unlock full historical data
See years of past statements with Premium.
Unlock with Premium
Insider Trading Volume
$164.24$148.98$133.72$118.46$103.20 Close Price0.00M0.62M1.23M1.85M2.47MUSD Trades VolumeAugSepOctNovDec2026FebMarAprMayJunJulAug
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
Dolsten MikaelDirectorMay 29 '26Sale135.421,600216,6725,548Jun 02
Dolsten MikaelDirectorDec 01 '25Sale149.812,600389,5114,973Dec 03
Gonsalves RodneyV.P., Corporate ControllerNov 26 '25Sale154.993,000464,95631,846Dec 01
MCDONNELL PADRAIGPresident and CEONov 18 '25Sale143.24911130,49232,058Nov 20
MCDONNELL PADRAIGPresident and CEONov 12 '25Option Exercise109.8612,4901,372,15145,938Nov 14
MCDONNELL PADRAIGPresident and CEONov 12 '25Sale150.0012,4901,873,50033,448Nov 14
MCDONNELL PADRAIGPresident and CEOSep 02 '25Sale124.882,000249,76033,448Sep 04
MCDONNELL PADRAIGPresident and CEOAug 01 '25Sale113.452,000226,90035,448Aug 04
MCDONNELL PADRAIGPresident and CEOJul 01 '25Sale117.441,508177,10037,448Jul 03
Brown Judy LDirectorJun 18 '25Sale116.5389041,677Jun 23
Podolsky Daniel KDirectorMar 31 '25Sale116.461,819211,84435,737Apr 02
Gonsalves RodneyV.P., Corporate ControllerMar 17 '25Sale121.981,908232,69121,786Mar 18
Rataj Sue H.DirectorMar 06 '25Sale126.386,971881,00919,640Mar 07
MCDONNELL PADRAIGPresident and CEOJan 21 '25Sale150.001,911286,65039,652Jan 23
MCDONNELL PADRAIGPresident and CEOSep 27 '24Sale150.00477,05024,071Sep 30
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.